Market Overview

UPDATE: Goldman Sachs Raises PT to $6.60 on Boston Scientific Following Q4 Takeaways

Share:
Related BSX
Earnings Scheduled For July 23, 2015
Boston Scientific Initiates Study Evaluating New Fully Resorbable Scaffold Technology
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

Goldman Sachs maintained Boston Scientific Corporation (NYSE: BSX) with a Sell rating and raised the price target from $5.20 to $6.60.

Goldman Sachs noted, "Following 4Q12 results, we adjust our 2013-2016E EPS to reflect: (1) increased sales across most businesses, aside from CRM; (2) revised gross margin assumptions; (3) higher operating expenses; (4) higher interest expense; and (5) increased share repurchases. Still, our revised 2013 sales estimate is now at the low end of guidance (-1.6% vs. the guidance midpoint at -0.7%), as we remain cautious on Boston's business exposure and relative share position."

Boston Scientific closed at $7.10 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015Stephens & Co.Initiates Coverage onOverweight
Apr 2015BarclaysMaintainsOverweight

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Get Benzinga's Newsletters